SARC029: A Phase 2 Study of Trametinib in Combination With Pazopanib in Patients With Advanced GIST (Gastrointestinal Stromal Tumor) Refractory or Intolerant to at Least Imatinib and Sunitinib

Trial Profile

SARC029: A Phase 2 Study of Trametinib in Combination With Pazopanib in Patients With Advanced GIST (Gastrointestinal Stromal Tumor) Refractory or Intolerant to at Least Imatinib and Sunitinib

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Pazopanib (Primary) ; Trametinib (Primary)
  • Indications Gastrointestinal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Mar 2017 Status changed from not yet recruiting to withdrawn prior to enrolment as supporting company withdrew interest
    • 28 Mar 2016 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020 as reported by ClinicalTrials.gov.
    • 28 Mar 2016 Planned initiation date changed from 1 Jan 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top